AstraZeneca Unveils Early Data From Chinese-Firm Partnered Oral Weight Loss Drug

At the ObesityWeek 2024, AstraZeneca Plc (NASDAQ:AZN) shared data abstracts highlighting early data from AZD5004/ECC5004.

In November 2023, AstraZeneca announced an exclusive license agreement with Eccogene for potential obesity treatment, ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist.

Eccogene received an initial upfront payment of $185 million. In addition, Eccogene will also receive up to an additional $1.825 billion in future milestone payments.

Also Read: AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race

The company shared data from a double-blind, randomized, placebo-controlled study of ECC5004 in healthy participants in single doses ...